Dapagliflozin improves hemoglobin and anemia in chronic kidney disease: a systematic review and meta-analysis.

Ren FailApr 23, 2026 (epub)
Clinical ResearchNephrologyHematologyOpen access

Annida Naufal Irvania, Ghazwan Andes Ats Tsauri, Anglita Yantisetiasti et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of dapagliflozin on anemia in patients with chronic kidney disease (CKD). The analysis included eight studies and found a significant increase in hemoglobin (MD = 4.37; 95% CI = 0.71-8.03; p = 0.02) and hematocrit (MD = 2.15; 95% CI = 1.86-2.44; p < 0.00001), suggesting potential benefits in managing anemia in CKD.

Key findings

  • Dapagliflozin significantly increased hemoglobin levels (MD = 4.37; 95% CI = 0.71-8.03; p = 0.02).
  • A significant increase in hematocrit was observed (MD = 2.15; 95% CI = 1.86-2.44; p < 0.00001).
  • Dapagliflozin reduced the overall risk of adverse events (RR = 0.77; 95% CI = 0.59-0.99; p = 0.04).
  • There was a significant reduction in mortality associated with dapagliflozin (RR = 0.67; p = 0.02).

Why it matters

The findings indicate that dapagliflozin may offer a new approach to managing anemia in CKD patients, potentially improving patient outcomes while reducing the risk of adverse events and mortality.

Source

PubMed · PMID 42021630Free full text on PubMed Central

Published in Ren Fail. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.